Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 13/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | TPMT | P51580 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24894275 | 0.77 | APP (0.38) | APPCA1CA2CA9RXRA | |
| SCHEMBL12585158 | 0.76 | ACHE (0.50) | CA1CA2CA9CYP3A4 | |
| SCHEMBL21295142 | 0.74 | NFE2L2 (0.41) | APPCA1CA2CA9 | |
| SCHEMBL3146571 | 0.74 | TDP1 (0.52) | APPCYP3A4 | |
| SCHEMBL5422997 | 0.74 | LMNA (0.42) | APPCA1CA2CA9CYP3A4 | |
| SCHEMBL27883059 | 0.73 | IDO1 (0.32) | APPIDO1 | |
| SCHEMBL2354326 | 0.72 | CA4 (0.48) | CA1CA2CA9 | |
| SCHEMBL11255612 | 0.69 | — | — | |
| SCHEMBL24567 | 0.69 | — | — | |
| SCHEMBL3841043 | 0.67 | LTA4H (0.50) | APPCA1CA2CA9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110003123-B | Modulators of the PGI2 receptor for the treatment of prostacyclin (PGI 2) receptor related disorders | 艾尼纳制药公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-110678450-B | Isoxazole derivatives as nuclear receptor agonists and uses thereof | 日东制药株式会社 | 2023-06-20 | — | — | CN | disclosed |
| CN-111511750-B | Macrocyclic derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2023-06-13 | — | — | CN | disclosed |
| CN-115315263-A | Cell surface receptor binding compounds and conjugates | 利西亚治疗公司 | 2022-11-08 | — | — | CN | disclosed |
| EP-3700911-A1 | NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Les Laboratoires Servier SAS (FR) | 2020-09-02 | — | — | EP | disclosed |
| CN-107406424-B | Estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2020-08-25 | — | — | CN | disclosed |
| CN-111511750-A | Novel macrocyclic derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2020-08-07 | — | — | CN | disclosed |
| CN-110678450-A | Isoxazole derivatives as nuclear receptor agonists and uses thereof | 日东制药株式会社 | 2020-01-10 | — | — | CN | disclosed |